BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 22782858)

  • 1. Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs.
    Benayoun L; Gingis-Velitski S; Voloshin T; Segal E; Segev R; Munster M; Bril R; Satchi-Fainaro R; Scherer SJ; Shaked Y
    Stem Cells; 2012 Sep; 30(9):1831-41. PubMed ID: 22782858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro enrichment of tumor-initiating cells from human established cell lines.
    Benayoun L; Shaked Y
    Curr Protoc Stem Cell Biol; 2013 Feb; Chapter 3():Unit 3.7. PubMed ID: 23404675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
    Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
    Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic therapy of head and neck squamous cell carcinoma by vascular endothelial growth factor antisense therapy.
    Riedel F; Götte K; Hörmann K; Grandis JR
    Adv Otorhinolaryngol; 2005; 62():103-20. PubMed ID: 15608422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphomimetic mutants of pigment epithelium-derived factor with enhanced antiangiogenic activity as potent anticancer agents.
    Konson A; Pradeep S; Seger R
    Cancer Res; 2010 Aug; 70(15):6247-57. PubMed ID: 20610633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor endothelial marker 7 (TEM-7): a novel target for antiangiogenic therapy.
    Bagley RG; Rouleau C; Weber W; Mehraein K; Smale R; Curiel M; Callahan M; Roy A; Boutin P; St Martin T; Nacht M; Teicher BA
    Microvasc Res; 2011 Nov; 82(3):253-62. PubMed ID: 21958527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
    Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth.
    Nör JE; Christensen J; Liu J; Peters M; Mooney DJ; Strieter RM; Polverini PJ
    Cancer Res; 2001 Mar; 61(5):2183-8. PubMed ID: 11280784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Squalamine and cisplatin block angiogenesis and growth of human ovarian cancer cells with or without HER-2 gene overexpression.
    Li D; Williams JI; Pietras RJ
    Oncogene; 2002 Apr; 21(18):2805-14. PubMed ID: 11973639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice.
    Keyes KA; Mann L; Sherman M; Galbreath E; Schirtzinger L; Ballard D; Chen YF; Iversen P; Teicher BA
    Cancer Chemother Pharmacol; 2004 Feb; 53(2):133-40. PubMed ID: 14593497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice.
    Lamszus K; Jin L; Fuchs A; Shi E; Chowdhury S; Yao Y; Polverini PJ; Laterra J; Goldberg ID; Rosen EM
    Lab Invest; 1997 Mar; 76(3):339-53. PubMed ID: 9121117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.